Jennison Associates LLC Purchases 2,226 Shares of Amedisys Inc (NASDAQ:AMED)

Jennison Associates LLC grew its position in shares of Amedisys Inc (NASDAQ:AMED) by 34.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,634 shares of the health services provider’s stock after purchasing an additional 2,226 shares during the quarter. Jennison Associates LLC’s holdings in Amedisys were worth $1,064,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMED. Alpha Quant Advisors LLC grew its position in Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after acquiring an additional 137 shares during the last quarter. Financial Gravity Companies Inc. bought a new position in Amedisys during the 4th quarter worth approximately $50,000. Captrust Financial Advisors grew its position in Amedisys by 161.8% during the 4th quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after acquiring an additional 369 shares during the last quarter. Group One Trading L.P. bought a new position in Amedisys during the 4th quarter worth approximately $90,000. Finally, Meeder Asset Management Inc. grew its position in Amedisys by 102.3% during the 1st quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after acquiring an additional 488 shares during the last quarter. Hedge funds and other institutional investors own 86.30% of the company’s stock.

AMED has been the topic of several recent research reports. SunTrust Banks raised their price target on Amedisys to $145.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. ValuEngine lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 27th. Barclays raised their price target on Amedisys from $115.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 21st. Finally, Craig Hallum reduced their price target on Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. They noted that the move was a valuation call. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $129.89.

NASDAQ AMED traded down $0.42 on Wednesday, hitting $117.18. The company’s stock had a trading volume of 5,741 shares, compared to its average volume of 454,129. Amedisys Inc has a 52-week low of $80.01 and a 52-week high of $140.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91. The stock has a market cap of $3.70 billion, a P/E ratio of 31.89, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, April 30th. The health services provider reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.22. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The business had revenue of $467.34 million during the quarter, compared to analysts’ expectations of $460.83 million. During the same quarter last year, the business posted $0.79 EPS. The business’s revenue was up 17.0% on a year-over-year basis. Sell-side analysts predict that Amedisys Inc will post 4.08 earnings per share for the current year.

In other Amedisys news, insider Michael Paul North sold 5,248 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $115.01, for a total value of $603,572.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce D. Perkins acquired 2,500 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $111.84 per share, with a total value of $279,600.00. Following the acquisition, the director now owns 22,088 shares in the company, valued at approximately $2,470,321.92. The disclosure for this purchase can be found here. In the last quarter, insiders sold 30,168 shares of company stock valued at $3,456,343. Company insiders own 2.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2019/06/12/jennison-associates-llc-purchases-2226-shares-of-amedisys-inc-nasdaqamed.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.